Objectives: This study aimed to evaluate the intraoperative findings, recurrence rate, and hearing outcome of cholesteatoma surgery and correlate them with the newly proposed EAONO/JOS Joint Consensus Statement.
Materials And Methods: The records of 407 patients diagnosed with chronic otitis media and cholesteatoma between 2009 and 2017 were reviewed. After the exclusion of records with unsatisfactory surgical notes and anamnesis, 353 patients were included in the study. The 290 patients who had undergone primary surgery and 63 who had undergone revision surgery were evaluated separately.
Results: Total 162 of 290 (56%) patients had retraction pocket cholesteatoma and 128 of 290 (44%) patients had non-retraction pocket cholesteatoma. Eighty (28%) patients had stage I, 114 (39%) had stage II, 91 (31%) had stage III, and 5 (2%) had stage VI disease. The recurrence rate was 6.9% (20/290). The average age of these patients at the time of the second operation was 23.31±10.3 years. Twelve patients had (60%) recurrent cholesteatoma, and eight (40%) had residual cholesteatoma. Hearing outcome and surgical technique were significantly associated with the disease stage; however, the recurrence rate showed no such association.
Conclusion: We concluded that the EAONO/JOS staging system is beneficial for estimating the postoperative hearing results and planning the surgical technique. However, there was no significant relationship between the recurrence rate and the EAONO/JOS staging system. We believe that additional factors, such as infection, ossicles, and invasion, predict the recurrence. Widespread use of the EAONO/JOS staging system will enable better evaluation of surgical outcomes and prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224431 | PMC |
http://dx.doi.org/10.5152/iao.2020.7598 | DOI Listing |
Int J Pediatr Otorhinolaryngol
December 2024
Department of Otolaryngology, University of Minnesota, Minneapolis, MN, USA; HealthPartners Medical Group, St. Paul, MN, USA. Electronic address:
Laryngoscope
October 2024
Université Paris Cité, UFR de Médecine, Paris, France.
Objective: The objective was to assess Potsic, EAONO/JOS, STAMCO, and ChOLE cholesteatoma staging systems in a large homogenous pediatric cohort with long-term follow-up and propose an evidence-based improved version.
Study Design: Cohort study.
Setting: Retrospective study in a tertiary referral center.
Healthcare (Basel)
August 2024
Department of Otorhinolaryngology, Tokyo Teishin Hospital, Tokyo 102-8798, Japan.
Cholesteatoma is a benign tumor of the middle ear. Tympanoplasty is performed to remove cholesteatoma, prevent recurrence, and avoid complications. Previously, microscopy was used for tympanoplasty; however, endoscopy has become increasingly popular for this procedure.
View Article and Find Full Text PDFOtolaryngol Clin North Am
February 2025
Department of Otolaryngology, Stanford University, Palo Alto, CA, USA. Electronic address:
Surgery for cholesteatoma should be tailored to individual patients, considering demographic and disease factors, to obtain a dry, safe, and functional ear. The EAONO/JOS classification and staging system provide a valuable framework for data collection and outcome assessment. Canal wall-up and canal wall-down surgical approaches each have their advantages and disadvantages, though it is not definitive that one approach is clearly more advantageous than the other.
View Article and Find Full Text PDFIndian J Otolaryngol Head Neck Surg
August 2024
Bacterial Pathogenesis Group, Infectious Diseases and Immunology Group, Translational Health Sciences and Technology Institute, Faridabad, Haryana 121001 India.
Introduction: Cholesteatoma usually harbors a poly-microbial infection. As the diversity of bacterial pathogens in the Indian COM is unknown, we set out to identify the bacteria associated with cholesteatoma disease in different patients of North India using targeted metagenomic analysis of the 16 S rRNA gene.
Methods: We recruited 15 patients of cholesteatomatous chronic otitis media (COM), who underwent surgical disease clearance.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!